Roger Lyons, MD, FACP, Discusses Real-World Treatment, Survival Patterns in Patients with MDS
By Cecilia Brown, Roger Lyons, MD, FACP - Last Updated: January 11, 2023Roger Lyons, MD, FACP, discusses a real-world retrospective observational study on treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting. Dr. Lyons and colleagues presented the research at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Post Tags:MDS ASH 22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.